bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totalling 225,800 shares, a decline of 15.5% from the August 15th total of 267,100 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 2,258.0 days.
bioMérieux Price Performance
Shares of BMXMF stock opened at $122.50 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.03 and a quick ratio of 1.19. bioMérieux has a one year low of $90.23 and a one year high of $122.52. The company’s 50-day moving average is $109.42 and its 200 day moving average is $105.93.
Wall Street Analyst Weigh In
Separately, UBS Group upgraded bioMérieux to a “strong-buy” rating in a research note on Thursday, August 22nd.
bioMérieux Company Profile
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
- Five stocks we like better than bioMérieux
- 3 Best Fintech Stocks for a Portfolio Boost
- e.l.f. Beauty: The High-Growth Stock You Shouldn’t Ignore
- Why Are These Companies Considered Blue Chips?
- Boeing’s Setback Could Be Investors’ Big Opportunity: Here’s Why
- Why Invest in High-Yield Dividend Stocks?
- What the Bulls and Bears Are Saying About NVIDIA Stock
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.
